Amylyx Pharmaceuticals (AMLX) Gross Profit (2022 - 2024)

Amylyx Pharmaceuticals' Gross Profit history runs 3 years deep, the most recent figure standing at -$636000.0 for Q4 2024.

• On a quarterly basis, Gross Profit fell 100.64% year-over-year to -$636000.0 in Q4 2024; TTM through Sep 2025 was -$636000.0, a 100.35% decrease from a year earlier, with the FY2024 full-year figure at $81.4 million, down 77.08% from the prior year.
• Gross Profit retreated to -$636000.0 in Q4 2024 per AMLX's latest filing, from $416000.0 in the prior quarter.
• Across five years, Gross Profit topped out at $99.1 million in Q4 2023 and bottomed at -$636000.0 in Q4 2024.
• The 3-year median for Gross Profit is $42.6 million (2022), against an average of $45.8 million.
• Across the five-year window, Gross Profit surged 56243.93% in 2023 and plunged 100.64% in 2024, its largest moves.
• Year by year, Gross Profit stood at $19.1 million in 2022, then soared by 419.77% to $99.1 million in 2023, then plunged by 100.64% to -$636000.0 in 2024.
• Per Business Quant, the three latest AMLX Gross Profit figures stand at -$636000.0 (Q4 2024), $416000.0 (Q3 2024), and $1.0 million (Q2 2024).